OUTLOOK THERAPEUTICS INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei OUTLOOK THERAPEUTICS INC listata cu simbolul US.OTLK ==Descriere companie== Outlook Therapeutics, Inc. (https://outlooktherapeutics.com/) is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associa...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Outlook Therapeutics, Inc. (https://outlooktherapeutics.com/) is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. The Company is developing a product candidate namely ONS-5010 (LYTENAVA (bevacizumab-vikg)), which is an investigational ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The Company’s product candidate ONS-5010 for wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. It is also developing ONS-5010 (LYTENAVA (bevacizumab-vikg)) for the treatment of diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). | Outlook Therapeutics, Inc. (https://outlooktherapeutics.com/) is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. The Company is developing a product candidate namely ONS-5010 (LYTENAVA (bevacizumab-vikg)), which is an investigational ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The Company’s product candidate ONS-5010 for wet AMD involves three clinical trials, which includes NORSE [[One|ONE]], NORSE TWO and NORSE THREE. It is also developing ONS-5010 (LYTENAVA (bevacizumab-vikg)) for the treatment of diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 2 octombrie 2024 16:53
Pagina dedicata companiei OUTLOOK THERAPEUTICS INC listata cu simbolul US.OTLK
Descriere companie[edit | ]
Outlook Therapeutics, Inc. (https://outlooktherapeutics.com/) is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. The Company is developing a product candidate namely ONS-5010 (LYTENAVA (bevacizumab-vikg)), which is an investigational ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The Company’s product candidate ONS-5010 for wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. It is also developing ONS-5010 (LYTENAVA (bevacizumab-vikg)) for the treatment of diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).
Grafic actiuni companie[edit | ]